Trial · NCT03333486
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Relapse Rate | At 1 year | The number of participants that relapse within 1 year. |
| Secondary | ANC Engraftment Rate, the Percentage of Participants That Had a Successful Engraftment | At 1 year post-transplant | Absolute Neutrophil Count Engraftment rate was defined as the number of participants that received an engraftment within 1 year post-transplant and ANC \> 0.5x10\^9/L for three consecutive days, out of the total number of participants. The rate was computed with corresponding exact 95% confidence intervals based on the methodology of Clopper and Pearson. |
| Secondary | Platelet Engraftment Rate, the Percentage of Participants That Had a Successful Engraftment | At 1 year post-transplant | Platelet Engraftment rate was defined as the number of participants that received an engraftment within 1 year post-transplant and the platelets \>= 20 x 10\^9/L after 7 consecutive days with no platelet transfusions, out of the total number of participants. The rate was computed with corresponding exact 95% confidence intervals based on the methodology of Clopper and Pearson. |
| Secondary | Proportion of Participants With Acute Graft Versus Host Disease (GVHD) | At 100 days post-transplant | Will be computed with corresponding exact 95% confidence intervals based on the methodology of Clopper and Pearson. |
| Secondary | Proportion of Participants With Chronic Graft Versus Host Disease (GVHD) | At 1 year post-transplant | Will be computed with corresponding exact 95% confidence intervals based on the methodology of Clopper and Pearson. |
| Secondary | Overall Survival | up to 5 years and 8 months | Will be computed with corresponding exact 95% confidence intervals based on the methodology of Clopper and Pearson. Will be obtained using the product-limit based Kaplan-Meier method. |
| Secondary | Progression Free Survival | up to 5 years and 8 months | Will be computed with corresponding exact 95% confidence intervals based on the methodology of Clopper and Pearson. Will be obtained using the product-limit based Kaplan-Meier method. |
| Secondary | Transplant Related Mortality | At 1 year post-transplant | Will be computed with corresponding exact 95% confidence intervals based on the methodology of Clopper and Pearson. |
| Other | Immune Reconstitution | Up to 1 year | Will be assessed by bone marrow transplantation SOC immunophenotyping panel and by analysis of cytomegalovirus-specific immunity. |
| Other | Lymphoid Chimerism Expressed as a Percentage of Donor Cells | At 30 days | Mean lymphoid chimerism expressed as a percentage of donor cells |
| Other | Myeloid Chimerism Expressed as a Percentage of Donor Cells | At 100 days | Mean myeloid chimerism expressed as a percentage of donor cells |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03333486/registered